LMRI · Lumexa Imaging Holdings, Inc.
$11.72
+0.04 (+0.34%)
At close · Aug 21
Market Cap
$1.14B
Shares
96.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.68
Open$11.73
Day$11.44–11.98
Available close range$6.77–18.53
Avg vol 30d489K
Short int2.8M · 2.9% float · 8.5d
Short vol24%
Last earningsAug 12, 2026
DataDec 2025–Aug 2026
Filing10-Q · Aug 13
The closing range uses available history since Dec 11, 2025; less than a full year is stored.
Up next
Next earnings call
Oct 21, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+6%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
42%
mid-range
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−17%
trailing
YTD return
−37%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+13% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.87% of float · ▲ +9.5% MoM · 8.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
102 holders — 13F breadth
Squeeze score
64
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 12, 2026
full year 2026
Adjusted EBITDA
Non-GAAP
Initiated
$235M – $241M
per quarter
Cash capex
$5M – $7M
2026
Adjusted EPS
Non-GAAP
$0.71 – $0.77
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+6%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+13% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.87% of float · ▲ +9.5% MoM · 8.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
102 holders — 13F breadth
Price context
position in its available closing range
Range low $7
Now $12 · 42%
Range high $19
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Consolidated outpatient same-center net revenue per scan growth | 0.6% | the three months ended June 30, 2026 filing | — |
| Consolidated outpatient same-center volume growth | 1.6% | the three months ended June 30, 2026 filing | — |
| Consolidated professional same-practice net revenue per read growth | 0.6% | the three months ended June 30, 2026 filing | — |
| Consolidated professional same-practice revenue growth | 5.1% | the three months ended June 30, 2026 filing | — |
| Consolidated professional same-practice volume growth | 4.6% | the three months ended June 30, 2026 filing | — |
| Consolidated revenue growth | 5.1% | the three months ended June 30, 2026 filing | — |
| Consolidated same-center revenue growth | 2.2% | Three months ended June 30, 2026 filing | — |
| System-wide outpatient same-center net revenue per scan growth | 2.2% | the three months ended June 30, 2026 filing | — |
| System-wide outpatient same-center revenue growth | 4.4% | the three months ended June 30, 2026 filing | — |
| System-wide outpatient same-center volume growth | 2.2% | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $56.4M | Q2 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 21.4% | Q2 2026 | — |
|
|
|||
| Consolidated advanced outpatient volume growth | 6.8% | Q2 2026 | — |
| Same-center advanced outpatient volume growth (consolidated) | 5.2% | Q2 2026 | — |
| Same-center advanced outpatient volume growth (system-wide) | 4.9% | Q2 2026 | — |
| System-wide advanced outpatient volume growth | 6.3% | Q2 2026 | — |
| System-wide revenue growth | 6% | Q2 2026 | — |
| % advanced procedures (consolidated) | 31.1% | 1Q26 | — |
| Consolidated advanced procedures | 182,176 | 1Q26 | — |
| Consolidated total procedures | 586,337 | 1Q26 | — |
| Same center advanced volume growth (consolidated) | 5.6% | Q1 2026 | — |
| Same center advanced volume growth (system-wide) | 5.6% | Q1 2026 | — |
| System-wide advanced procedures | 357,592 | 1Q26 | — |
| System-wide total procedures | 966,934 | 1Q26 | — |
| Expected Adjusted EBITDA non-GAAP | $229M | Full Year 2025 | — |
| Expected system-wide revenue growth | 8% | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LMRI
this stock
Lumexa Imaging Holdings, Inc.
|
$1.14B | -36.9% | — | — | 2.9% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LMRI | -4.3% | +8.7% | -17.4% | +12.2% | -36.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -2.3% | +5.3% | -28.6% | +10.1% | -48.7% |
Key facts
CIK
2071288
CUSIP
550249106
13F (30d)
98 filings
97 filers
Visit website
Investor relations